Evidence map›Paper›PMID 33333255›Full record

ReviewClinical immunology (Orlando, Fla.)2021

Interrelations between COVID-19 and other disorders.

Amin Gasmi, Massimiliano Peana, Lyudmila Pivina, Shvetha Srinath, Asma Gasmi Benahmed, Yuliya Semenova, Alain Menzel, Maryam Dadar, Geir Bjørklund

Open access · greenAbstract readReview
In one paragraph

Review in Clinical immunology (Orlando, Fla.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
102citing papers in PubMed, 2 pooled it
3.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

102 citing papers in PubMed, 2 syntheses or guidelines pooled it, 186 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Observational
  18. Article
  19. Review
  20. Asthma as a risk factor and allergic rhinitis as a protective factor for COVID-19 severity: a case-control study.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2024
    Article

42 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 5 countries.

Amin GasmiSociété Francophone de Nutrithérapie et de Nutrigénétique Appliquée, Villeurbanne, France.
Massimiliano PeanaDepartment of Chemistry and Pharmacy, University of Sassari, Sassari, Italy. Electronic address: peana@uniss.it.
Lyudmila PivinaSemey Medical University, Semey, Kazakhstan; CONEM Kazakhstan Environmental Health and Safety Research Group, Semey Medical University, Semey, Kazakhstan.
Shvetha SrinathSociété Francophone de Nutrithérapie et de Nutrigénétique Appliquée, Villeurbanne, France.
Asma Gasmi BenahmedAcadémie Internationale de Médecine Dentaire Intégrative, Paris, France.
Yuliya SemenovaSemey Medical University, Semey, Kazakhstan; CONEM Kazakhstan Environmental Health and Safety Research Group, Semey Medical University, Semey, Kazakhstan.
Alain MenzelLaboratoires Réunis, Junglinster, Luxembourg.
Maryam DadarRazi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran.
Geir BjørklundCouncil for Nutritional and Environmental Medicine (CONEM), Mo i Rana, Norway. Electronic address: bjorklund@conem.org.
Semey Medical University · KZSociété Francophone d’Arthroscopie · FRAgricultural Research & Education Organization · IRThe Research Council of Norway · NOUniversity of Sassari · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a respiratory tract virus that causes Coronavirus disease (COVID-19). The virus originated in Wuhan, China, in December 2019 and has spread across the globe to-date. The disease ranges from asymptomatic carriers to symptoms such as fever, sore throat, cough, lung infections, and in severe cases, acute respiratory distress syndrome, sepsis, and death. As many as 50% of patients reported having at least one comorbidities with COVID-19 upon hospital admission. Hypertension, diabetes, chronic obstructive pulmonary disease, obesity, and cardiovascular diseases are among the most commonly reported. Comorbidities are contributing to acute disease prognosis and increased risk of severe symptoms. Around 70% of patients who require ICU care have been observed to have comorbidities. This review intends to understand how some of these comorbidities affect the disease's prognosis and how severe the outcome can be expected.

Indexed as

Cardiovascular DiseasesComorbidityCOVID-19Diabetes MellitusHumansHypertensionObesityPulmonary Disease, Chronic ObstructiveSARS-CoV-2AsthmaCardiovascular diseasesComorbiditiesCOVID-19DiabetesHypertensionNovel coronavirusPreexisting conditionSARS-CoV-2 outcomeSevere outcome

Identifiers

PMID33333255
PMCPMC7833539
OpenAlexW3113195110

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.